论文部分内容阅读
目的 探讨CD3AK细胞过继治疗对原发性肝癌（PLC）患者T淋巴细胞亚群及功能活性的影响。方法 58例 PLC患者分为:CD3AK细胞治疗组（n=37）,对照组（n=21）,另取11例献血员为正常对照。治疗组术后第1天开始输注CD3AK细胞,每天1次,每次输注2x109个细胞,输注前30min静脉注射IL-2100u,连续5d为一个疗程;对照组只给予与治疗组相同的保肝治疗。观察两组T淋巴细胞亚群、IL-2R、细胞增殖功能、NK及LAK活性。结果 治疗组CD4/CD8比值、NK活性、LAK活性、IL-2R表达水平及细胞增殖活力与治疗前和对照组比较,差异均有显著性意义。结论 过继输注CD3AK细胞治疗能够补充肝癌患者有效抗肿瘤活性细胞数量的不足,并能够使T淋巴细胞亚群比例失调和功能低下的状况获得不同程度的改善。
Objective To investigate the effect of adoptive therapy of CD3AK cells on T lymphocyte subsets and functional activity in patients with primary hepatocellular carcinoma (PLC). Methods Fifty-eight patients with PLC were divided into three groups: control group (n = 37) and CD3AK cell treatment group (n = 21). Another 11 blood donors were used as normal control. The treatment group received infusion of CD3AK cells on day 1 postoperatively once a day for 2 × 10 9 cells infusion of IL-2100u 30 min before infusion for 5 days for a course of treatment; the control group was given only the same treatment group Liver treatment. T lymphocyte subsets, IL-2R, cell proliferation, NK and LAK activity were observed in both groups. Results The difference of CD4 / CD8 ratio, NK activity, LAK activity, IL-2R expression level and cell proliferation activity in treatment group were significantly different from those before treatment and in control group. CONCLUSION: The adoptive infusion of CD3AK cells can supplement the effective anti-tumor activity of hepatocellular carcinoma cells, and can improve the degree of dysregulation and dysfunction of T lymphocyte subsets to some extent.